Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia

Last updated: February 4, 2009
Sponsor: Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Overall Status: Trial Status Unknown

Phase

4

Condition

Tardive Dyskinesia

Dyskinesias

Treatment

N/A

Clinical Study ID

NCT00837707
TMH-97-03
  • All Genders

Study Summary

The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Female patients must agree to prevent from being pregnant during trial periods

  • Meet psychotic disorder or mood disorder criteria of DSM-IV

  • Patients must have psychiatric diseases that need to use antipsychotics for a longtime

  • They must meet DSM-IV research criteria for neuroleptics induce tardive dyskinesia

  • No clinical significant major systemic diseases

  • No special neurological diseases which would influence the assessment for EPS or TD

  • Mentality is better than mild mental retardation

  • Patients or .legal representatives agree to join in the research and sign informedconsent.

Exclusion

Exclusion Criteria:

  • Unstable major systemic diseases

  • Had neurological disorder influenced to EPS assessment

  • Substance abuse or dependence other then coffee or tobacco within 6 months beforestudy

Study Design

Total Participants: 25
Study Start date:
June 01, 2008
Estimated Completion Date:
February 28, 2010

Study Description

Objective:A few case reports on the use of aripiprazole in neuroleptic-induced tardive dyskinesia have demonstrated positive effects. However its effectiveness in treatment of TD was still inconclusive. The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia.

Method: Subjects with pre-existing neuroleptic-induced tardive dyskinesia were chosen from Taoyuan psychiatric center. Patients recruited would be treated with aripiprazole for cross-titration with previous antipsychotics in 8 weeks. We use AIMS, SAS, & BAS to assess the severity of TF and EPS. We record subjects' age, sex, and other factors which have influence at the treatment response. Subjects are assessed every two weeks in the first month and then monthly until six months.

Connect with a study center

  • Taoyuan Mental Hospital

    Taoyuan, 330
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.